Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

November 30, 2022

https://www.globenewswire.com/news-release/2022/11/30/2564803/0/en/Oncorus-Announces-Portfolio-Reprioritization-to-Focus-on-IV-Administered-Self-Amplifying-RNA-Medicines-for-Patients-with-Cancer.html

ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeline to focus on its lead viral RNA (vRNA) immunotherapy product candidate, ONCR-021. In addition, the company is discontinuing the development of ONCR-177, reducing its workforce and burn rate and reiterating guidance for its cash runway into early 2024.

Read more at globenewswire.com

Related news for (ONCR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.